Literature DB >> 33121257

Short-Term Morbidity and Predictors of Adverse Events Following Esthesioneuroblastoma Surgery.

Khodayar Goshtasbi1, Jack L Birkenbeuel1, Mehdi Abouzari1, Brandon M Lehrich1, Tyler M Yasaka1, Arash Abiri1, Ethan G Muhonen1, Frank P K Hsu2, Edward C Kuan1.   

Abstract

INTRODUCTION: The short-term adverse events and predictors of morbidity in surgical resection of esthesioneuroblastoma (ENB) are largely unknown, and investigating these variables can help direct planning for at-risk patients.
METHODS: The 2005-2017 National Surgical Quality Improvement Program database was queried to identify patients with a diagnosis of ENB undergoing skull base surgery for tumor resection. Information regarding demographics, patient morbidity score, pre-operative and intra-operative data, and post-operative outcomes were extracted. Cox proportional hazard analysis was utilized to assess complication and readmission/reoperation rates.
RESULTS: A total of 95 patients undergoing skull base surgery for resection of ENB were included. Mean age, BMI, operation time, and post-operative length of stay (LOS) of the cohort were 53.6 ± 16.2 years, 29.1 ± 6.5, 392.0 ± 204.6 minutes, and 5.8 ± 4.6 days, respectively. In total, 31 patients (32.6%) experienced at least one 30-day adverse event, which included blood transfusion intra-operatively or within 72 hours from the operation (22.1%), readmission (10.7%), intubation >48 hours (7.4%), reintubation (4.2%), organ or space infection (4.2%), reoperation (4.0%), superficial or deep surgical site infection (2.1%), sepsis (2.1%), pulmonary embolism (1.1%), and myocardial infarction (1.1%). Patients who experienced at least one adverse event had significantly higher operation time (486.8 ± 230.4 vs. 347.5 ± 176.2 minutes, p = 0.002), LOS (9.2 ± 5.6 days vs. 4.2 ± 3.0, p < 0.001), and lower hematocrit (37.3 ± 5.9 vs. 41.2 ± 3.8, p < 0.001) and albumin levels (3.8 ± 0.6 vs. 4.2 ± 0.3, p = 0.009). Patients with a higher American Society of Anesthesiologists (ASA) score (HR = 2.39; p = 0.047) or longer operation time (HR = 1.004; p = 0.001) had a significantly higher risk for experiencing adverse events. Obesity was not associated with different intra- or post-operative outcomes, but older patients had shorter operations (p = 0.002) and LOS (p = 0.0014).
CONCLUSION: Longer operation time and lower pre-operative hematocrit and albumin levels may all increase complication rates in ENB resection. Patients with high ASA score or more advanced age may have different short-term outcomes.

Entities:  

Keywords:  National Surgical Quality Improvement Program; esthesioneuroblastoma; morbidity and mortality; olfactory neuroblastoma

Mesh:

Year:  2020        PMID: 33121257      PMCID: PMC8822193          DOI: 10.1177/1945892420970468

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  46 in total

1.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

2.  Association between Preoperative Albumin Levels and Length of Stay after Radical Cystectomy.

Authors:  Rohan G Bhalla; Li Wang; Sam S Chang; Mark D Tyson
Journal:  J Urol       Date:  2017-05-19       Impact factor: 7.450

3.  Predictors of perioperative complications in head and neck patients.

Authors:  D Gregory Farwell; Dominic F Reilly; Ernest A Weymuller; Deborah L Greenberg; Thomas O Staiger; Neal A Futran
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-05

Review 4.  Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis.

Authors:  Khodayar Goshtasbi; Arash Abiri; Mehdi Abouzari; Ronald Sahyouni; Beverly Y Wang; Bobby A Tajudeen; Frank P K Hsu; Gilbert Cadena; Edward C Kuan
Journal:  Int Forum Allergy Rhinol       Date:  2019-06-28       Impact factor: 3.858

5.  Preoperative Embolization for Skull Base Meningiomas.

Authors:  Kensuke Suzuki; Masaya Nagaishi; Yoshiyuki Matsumoto; Yoshiko Fujii; Yuki Inoue; Yoshiki Sugiura; Koji Hirata; Ryotaro Suzuki; Yosuke Kawamura; Ryuta Nakae; Yoshihiro Tanaka; Akio Hyodo
Journal:  J Neurol Surg B Skull Base       Date:  2017-02-15

6.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

7.  Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer.

Authors:  Karina de Cássia Braga Ribeiro; Luiz Paulo Kowalski; Maria do Rosário Dias de Oliveira Latorre
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-02

8.  Esthesioneuroblastoma: the UCLA experience 1970-1990.

Authors:  P Dulguerov; T Calcaterra
Journal:  Laryngoscope       Date:  1992-08       Impact factor: 3.325

9.  Pediatric Thyroidectomy: NSQIP-P Analysis of Adverse Perioperative Outcomes.

Authors:  Vijay A Patel; Aliasgher Khaku; Michele M Carr
Journal:  Ann Otol Rhinol Laryngol       Date:  2019-11-15       Impact factor: 1.547

10.  Impact of Operation Time on 30-Day Complications After Adult Spinal Deformity Surgery.

Authors:  Kevin Phan; Jun S Kim; John Di Capua; Nathan J Lee; Parth Kothari; James Dowdell; Samuel C Overley; Javier Z Guzman; Samuel K Cho
Journal:  Global Spine J       Date:  2017-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.